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Ataxia-telangiectasia and rad3 (ATR)-related Seckel syndrome is associated with growth retardation and premature aging 
features. ATR-Seckel fibroblasts have a reduced replicative capacity in vitro and an aged morphology that is associated 
with activation of stress-associated p38 mitogen-activated protein kinase and phosphorylated HSP27. These phenotypes 
are prevented using p38 inhibitors, with replicative capacity restored to the normal range. However, this stressed pheno-
type is retained in telomerase-immortalized ATR-Seckel fibroblasts, indicating that it is independent of telomere erosion. 
As with normal fibroblasts, senescence in ATR-Seckel is bypassed by p53 abrogation. Young ATR-Seckel fibroblasts 
show elevated levels of p21WAF1, p16INK4A, phosphorylated actin-binding protein cofilin, and phosphorylated caveolin-1, 
with small molecule drug inhibition of p38 reducing p16INK4A and caveolin-1 phosphorylation. In conclusion, ATR-Seckel 
fibroblasts undergo accelerated aging via stress-induced premature senescence and p38 activation that may underlie 
certain clinical features of Seckel syndrome, and our data suggest a novel target for pharmacological intervention in this 
human syndrome.
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SEGMENTAL progerias are human genetic syndromes that accelerate some, but not all, of the features of 
human aging and have long been used to explore geno-
type–phenotype relationships in human aging (1). In previ-
ous studies, we have focused on one of the most dramatic 
progeroid syndromes, that is, Werner syndrome (WS). Lack 
of WRNp (Werner syndrome RecQ helicase-like protein) 
leads to premature fibroblast senescence resulting from 
activation of the stress-associated p38 mitogen-activated 
protein (MAP) kinase, which is thus termed stress-induced 
premature senescence or SIPS (2). This SIPS has been pro-
posed to underlie some of the premature aging features seen 
in WS (3). We previously demonstrated that the dramatic 
shortening of WS cellular replicative life span observed in 
vitro could be rescued by treatment with p38 MAP kinase 
inhibitors (4). We hypothesized that loss of WRNp results 
in replication stress, activation of p38 MAP kinase, and 
premature whole-body aging as a result of upregulation of 
p38-dependent inflammatory molecules (inflamm-aging) 
and/or p38-driven premature senescence (5).
Subsequently, we explored a range of non-WS progerias 
and demonstrated that activation of p38 MAP kinase was not 
a widespread phenomenon (6,7). Many of these progeroid 
syndromes show defects in DNA repair and genome stabil-
ity, indicating that p38 activation in WS is not simply the 
result of generalized compromised genome integrity. We 
have also shown that patient-derived cells from Rothmund–
Thomson syndrome, a mild progeroid syndrome caused by 
mutations in another RecQ helicase, show activation of p38 
MAP kinase, albeit without a dramatic effect on replicative 
life span (8). This suggests that activation of p38 in prog-
erias is closely linked with a subset of biological processes 
related to genome stability.
Given the DNA replication defects observed in WS that 
include the stalling of DNA replication forks (9), and our 
hypothesis that such defects are an upstream driver of p38 
activation in WS (5), we sought to examine additional 
progeroid syndromes carrying mutations in the same axis 
to ask whether they also showed activation of p38, and 
in this study, we focused on the ataxia-telangiectasia and 
rad3 (ATR)-related checkpoint kinase. Although ATR is an 
essential gene, viable mutations in ATR are found in a sub-
set of human Seckel syndrome individuals (10).
Seckel syndrome is a rare heterogeneous autosomal 
recessive disorder found in less than 1 in 10,000 live births 
(11). Mutations have been found in five genes in Seckel 
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syndrome that includes the ATR gene (SCKL1) in the ATR-
Seckel variant (12). The rarity of ATR-Seckel patients 
is consistent with the observation that null mutations in 
ATR appear to be lethal; no human examples of viable 
homozygous ATR null mutations have been identified and 
experimental-induced null mutations of ATR are lethal in 
the mouse (13). ATR-Seckel thus appears to be a rare viable 
hypomorphic allele (10).
Seckel syndrome is characterized by intrauterine growth 
retardation, developmental delay, bird-like facies, severe 
microcephaly, and short stature, as well as brain size reduc-
tion, cysts, and agenesis of the corpus callosum (11,14). 
Other symptoms include sparse hair, café-au-lait spots, 
impaired cardiovascular function, and age-related disor-
ders such as type II diabetes, all features seen in normal 
aging, and Seckel syndrome individuals die earlier than 
normal individuals (15). Thus, although Seckel syndrome 
appears to be primarily a “failure of growth” disorder, it 
is associated with mild progeroid features (10,16). This 
segmental progeroid nature of ATR-Seckel is not untypical 
of several of the recognized progeroid syndromes, where 
the premature aging features are not the primary pheno-
typic manifestations (1). It should also be noted that there 
appear to be no genes that specifically “cause aging”; the 
processes that affect aging involve gene products that have 
diverse additional functions in the body, so mutations in 
such genes will have broad-ranging phenotypic conse-
quences. However, premature aging is a primary feature 
seen in the ATR-Seckel mouse model (13). Human WS is 
also associated with growth retardation, as WS individu-
als fail to show the pubertal growth spurt and are short in 
height (17). Thus, ATR-Seckel shares with WS two pheno-
typic characteristics, that of premature aging and growth 
retardation.
ATR-Seckel was chosen for this study because of the 
hypothesized role of replication stress as a driver of the 
premature aging phenotype of WS fibroblasts. An impor-
tant function of ATR is the coordination of checkpoint 
control responses to replication fork stalling, which arises 
during normal replication, particularly at DNA sites that 
are difficult to replicate, including the so-called frag-
ile sites (10,18,19). ATR-Seckel fibroblasts are reported 
to grow slowly, have slow cycling time and increased 
chromosomal instability (CIN), especially at fragile sites 
(10,20,21), and show increased replication fork stalling 
(22). These features are replicated in a mouse ATR-Seckel 
model, with ATRS/S mouse embryonic fibroblasts (MEFs) 
showing slow growth, premature cellular senescence, and 
CIN at fragile sites and ATRS/S mice showing growth retar-
dation and premature aging (13). Human WS fibroblasts 
also show slow growth rates and premature senescence 
(4), an increase in replication fork stalling (9), and CIN 
at fragile sites (23). Common fragile sites are observed as 
nonstaining gaps or breaks in metaphase chromosomes of 
cells cultured under conditions of replicative stress. These 
reproducible nonrandom fragile regions of chromosomes 
observed in vitro correspond to regions where specific 
DNA instability has been observed in vivo in various 
human cancers (24). WRNp deficiency recapitulates ATR 
defects in terms of fragile site instability either when cells 
are exposed to aphidicolin or under unperturbed condi-
tions (23). According to the model proposed by Casper and 
colleagues (20), ATR is activated after replication stress 
to stabilize and rescue stalled replication forks. Similarly, 
WRNp appears to be essential for fruitful rescue from rep-
lication fork arrest (25–27) and is targeted for ATR phos-
phorylation upon replication arrest (28). It appears that 
ATR collaborates with and recruits WRNp to replication 
fork stalls in a DNA damage pathway that responds to 
replication stress, particularly due to problems inherent 
in the replication of fragile site regions to aid replication 
fork recovery and to restart DNA synthesis (29). This idea 
is supported by the observation that ATR deficiency in WS 
fibroblasts does not increase the frequency of fragile site 
expression (ie, ATR and WRNp do not synergize), which 
is suggestive of a common pathway (23).
The interaction between ATR and WRNp in a common 
signalling pathway, the resemblance between WS and ATR-
Seckel cells, and the potential involvement of aberrant DNA 
replication in both syndromes led us to hypothesize that the 
premature aging seen in both syndromes may reflect an 
overlap in causal mechanisms. To address this hypothesis, 
we examined the mechanisms leading to cellular senes-
cence in ATR-Seckel by determining the growth character-
istics and replicative capability of ATR-Seckel fibroblasts 
and the role of p53 using shRNA abrogation in replicative 
senescence. In addition, we investigated the role played by 
p38 MAP kinase using a combination of molecular profil-
ing and small molecule inhibitor use. Furthermore because 
telomere shortening is a major mechanism driving fibro-
blast senescence and ATR deficiency results in telomere fra-
gility (30), we have also used ectopic expression of human 
telomerase to determine whether replicative senescence in 
ATR-Seckel fibroblasts is telomere dependent.
Materials and Methods
Cells and Cell Culture
The primary dermal fibroblasts used in this work were 
obtained from the Coriell Cell Repository (Camden, NJ); 
ATR-Seckel strain GM18366 that carries a hypomorphic 
ATR allele (31); three normal dermal fibroblast strains 
(NDFs) AG06234, AG13152, and AG16409; and the WS 
strain AG05229.
All cells were grown in Earle’s Modified Eagle medium 
(EMEM; Gibco) supplemented with 10% fetal calf serum 
(Autogen Bioclear, Witshire, UK) in an atmosphere of 20% 
O
2
 and 5% CO
2
, and passaged every 4–5 days exactly as 
described previously (4).
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Protein Kinase Inhibitors
SB203580 was obtained from Tocris Chemical Co. 
(Bristol, UK). BIRB 796 and VX-745 were synthesized 
according to Bagley and colleagues (32,33). For experi-
ments using inhibitors, growth medium was supplemented 
with SB203580 and BIRB 796 at 2.5 µM and VX-745 at 
0.5  µM. For controls, an equivalent volume of dimethyl 
sulfoxide was added to the medium. SB203580 at 2.5 µM 
is in the range used routinely for studying the effects of 
SB203580 on p38 activity in cell biological systems (6) and 
that does not inhibit the related JNK1/2 kinases (34). BIRB 
796 at 2.5 µM is the maximum concentration that inhib-
its p38 without inhibiting the related JNK1/2 kinases (34). 
VX-745 at 0.5  µM is the minimal concentration needed 
to maximally inhibit p38 (33). To maintain maximal p38 
inhibition, growth medium was replaced daily with fresh 
EMEM-containing p38 inhibitors.
Retroviral Gene Transfer
The ectopic expression of human telomerase protein and 
the expression of an shRNA against p53 in ATR-Seckel 
cells were exactly as described previously (8,35).
Immunofluorescence Microscopy
Actin staining with fluorescein isothiocyanate-conjugated 
(FITC)-phalloidin for immunofluorescence microscopy was 
performed exactly as described (4).
Immunoblot Analysis
Immunoblot analysis was done exactly as previously 
described (4). All antibodies have been previously described 
except anti-phospho(Y14)-caveolin-1 and anti-caveolin-1 
(Cell Signalling, New England Biolabs, Hitchin, UK 
[4,8,35,36]).
Results
Effects of p38 Inhibitors on the Growth of Normal and 
ATR-Seckel Fibroblasts
ATR-Seckel GM18366 fibroblasts were grown in triplicate 
to replicative senescence in the presence or absence of p38 
inhibitors. As shown in Figure 1A, GM18366 control cells 
had a replicative capacity of 19.3 ± 0.6 population doublings 
(PDs) that was not statistically shorter than the mean of three 
NDFs (Table 1; Figure 1B and C). The GM18366 replica-
tive capacity increased with each p38 inhibitor used with 
VX-745 having the smallest and BIRB 796 the largest effect 
(Figure 1A; Table 1). With BIRB 796, the GM18366 replica-
tive capacity was within the range of BIRB 796–treated NDFs 
(Table 1). The percentage increases in replicative capacity of 
GM18366 cells for each inhibitor compared with NDFs were 
all highly statistically significant (p < .0001; z test).
Visualization of F-Actin Stress Fibers in ATR-Seckel 
Fibroblasts
Low PD GM18366 cells stained with FITC-phalloidin 
showed many cells that were enlarged with numerous vis-
ible F-actin stress fibers (Figure 1D); in contrast, low PD 
AG16409 NDFs were smaller with few F-actin stress fibers 
(Figure 1H). When grown in the presence of p38 inhibitors, 
the morphology of GM18366 cells more resembled that of 
young NDFs (Figure 1E–G). The three inhibitors were not 
equally effective, however, with VX-745 having the small-
est effect with several enlarged cells with F-actin fibers 
remaining (Figure 1E). In contrast, the inhibitors had little 
effect on NDFs (not shown). When GM18366 cells reached 
M1, all the cells were enlarged with extensive stress fib-
ers (Figure 1I) and p38 treatment had no effect on this (not 
shown). Similar results were seen for AG16409 cells at M1 
(not shown).
ATR-Seckel Fibroblasts have Activated p38 and Stress 
Signalling
Activated (phosphorylated) p38 (p-p38) was detected by 
immunoblot assay in GM18366 young primary fibroblasts 
but not in young AG16409 cells (Figure 2). All three p38 
inhibitors reduced the level of p-p38 in GM18366 cells to 
some extent but didn’t abolish it (Figure 2A). The ability 
of p38 inhibitors to partially prevent p38 activation has 
been reported previously for VX-745 and SB203580 at 
the concentrations used here (33). BIRB 796 is reported 
to completely prevent phosphorylation of p38 at 10  µM 
but not at 1  µM (32,37); thus, it may be expected that 
BIRB 796 would only partially prevent p38 activation at 
the concentration of 2.5  µM used here. In contrast, p38 
inhibitors had no effect on the very low p-p38 levels in 
the AG16409 cells (Figure 2B). When the GM18366 cells 
reached M1, the levels of p-p38 increased (Figure 4F).
HSP27, a downstream target of the p38 pathway, was 
phosphorylated in GM18366 fibroblasts and, to a lesser 
extent, in AG16409 cells (Figure 2). Phosphorylation levels 
were reduced by all three inhibitors in the young GM18366 
cells; however, the inhibitors differed in their efficacy, with 
VX-745 having a small effect and BIRB 796 almost com-
pletely abolishing p-HSP27 levels. A similar effect was seen 
with AG16409 cells, although in this case, the p-HSP27 lev-
els were much lower in the AG16409 cells under all condi-
tions tested. The immediate p38 target MK2 is activated in 
young GM18366 cells as indicated by the doublet, and this 
was reduced in inhibitor-treated cells (Figure 3A). MK2 is 
the major HSP27 kinase (38).
The LIN-11/Isl1/MEC3-domain (LIM) kinase pathway 
is thought to be regulated by p38 signalling under some cir-
cumstances and regulates F-actin stress fiber expression via 
phosphorylation and inactivation of the actin depolymeriz-
ing factor cofilin (39). In low PD GM18366 cells, cofilin 
was phosphorylated compared with low PD AG16409 cells, 
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and the level of p-cofilin was only slightly reduced by p38 
inhibitors (Figure 3A), suggesting that the stress fiber phe-
notype is not via the LIM kinase pathway.
Expression of Cell Cycle Proteins in ATR-Seckel Cells
Low PD GM18366 cells showed elevated levels of the 
cyclin-dependent kinase inhibitors (CdkIs) p21WAF1 and 
p16INK4A compared with NDFs (Figure 3B). The effects of 
p38 inhibitors on this expression in GM18366 cells were 
mixed, with little effect seen on the levels of p21WAF1; 
however, the levels of p16INK4A were much reduced by 
all inhibitors used with SB203580 having the smallest 
effect. When the GM18366 cells reached M1, both CdkIs 
appeared to show small increases (Figure 4F). The tumor 
suppressor p53 protein was present at similar levels in 
both low PD GM18366 cells and GM18366 cells at M1 
(Figure 4F).
ATR-Seckel Cells have Phosphorylated Caveolin-1
Although elevated caveolin-1 expression is associated 
with premature fibroblast senescence (40), low PD ATR-
Seckel cells did not show elevated caveolin-1 levels com-
pared with low PD NDFs and p38 inhibitors had no effects 
on this expression (Figure 3A). However, ATR-Seckel cells 
Figure 1. Growth characteristics of ataxia-telangiectasia and rad3 (ATR)-related Seckel and normal dermal fibroblast (NDF) strains with or without p38 inhibitor 
treatment. (A) GM18366 cells, (B) AG06234 cells, and (C) AG16409 cells. Fibroblasts were grown in Earle’s Modified Eagle medium (EMEM) supplemented with 
0.1% (v/v) dimethyl sulfoxide (DMSO; ○) or the p38 inhibitors VX-745 (■), SB203580 (□), and BIRB 796 (●). Growth is measured as population doublings (PDs) 
vs days. Observation of F-actin stress fibers in (D–G) ATR-Seckel cells, (H) AG16409 cells, and (I) ATR-Seckel cells at M1. The conditions for growth are indicated 
on the panels. Bar = 100 μm.
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had activated (phosphorylated) caveolin-1 compared with 
low PD AG16409 cells (Figure 3A) as shown by elevated 
levels of the 21 kDa protein and the presence of the 24 kDa 
protein (indicated by arrow). Treatment of ATR-Seckel cells 
with p38 inhibitors decreased the levels of both phosphoryl-
ated protein variants with BIRB 796 treatment reducing the 
level of p-caveolin-1 to that seen in AG16409 cells. When 
GM18366 cells reached M1, the levels of p-caveolin-1 were 
reduced compared with low PD cells, whereas no changes 
in the levels of caveolin-1 were seen (Figure 4F). These data 
contrast with WS cells in that the levels of both caveolin-1 
and p-caveolin-1 are elevated in low PD WS fibroblasts 
compared with NDFs and both are reduced with the p38 
inhibitor SB203580 (Figure 3C).
Abrogation of p53 Allowed ATR-Seckel Cells to Bypass 
Senescence
Presenescent GM18366 fibroblasts at PD 17 were 
infected with amphotropic retroviral vectors encoding a 
puromycin resistance (puro) gene alone, or both puro and 
an shRNA to p53. Analysis of puromycin-resistant cultures 
(designated GM18366puro and GM18366p53, respectively) 
began 2–3 weeks after infection.
Cells expressing puro alone ceased proliferating within 
the first 2 weeks and entered a senescent-like state after 
achieving 1 PD (Figure 4A). The GM18366puro cells at this 
stage appeared essentially identical to uninfected GM18366 
Table 1. Life Span of Fibroblasts Grown in the Presence or Absence of p38 Inhibitors
Strain PD at Start*
PDs Achieved†
Control VX-745 %‡ SB203580 %‡ BIRB 796 %‡
Normal
 AG06234 15.0 36.8 41.6 22.0 44.4 34.8 45.6 40.4
 AG13152 6.0 28.0 31.7 16.8 35.6 34.5 38.3 46.8
 AG16409 4.0 54.3 54.3 0 61.9 15.1 67.3 25.8
Mean ± SD 39.7 ± 13.3 42.5 ± 11.3 12.9 ± 11.5 47.3 ± 13.4 28.1 ± 11.3 50.4 ± 15.1 37.7 ± 10.8
ATR-Seckel§
 GM18366 ± SD 7.5 19.3 ± 0.6 (3) 26.8 ± 0.6 (3) 63.6 28.3 ± 0.3 (3) 76.3 39.1 ± 1.8 (3) 167.8
 Probability (p)|| >.063 >.083 <.0001 >.079 <.0001 >.22 <.0001
Notes: PD = population doubling; SD = standard deviation.
*Reported PDs of cell strain when they were obtained from Coriell Repository.
†Total PDs achieved (this includes PDs at start plus PDs achieved during these growth experiments).
‡The percentage increase in replicative capacity is determined with reference to starting PD, eg, for AG06234, the replicative capacity increase using VX-745 is 
(41.6 PDs −15 PDs)/(36.8 PDs −15 PDs) = 1.22 or a 22.0% increase in experimental replicative capacity.
§All ataxia-telangiectasia and rad3-related (ATR)-Seckel cultures are grown in triplicate.
||Probability that this is same as for normal cells; z test.
Figure  2. Immunoblot analysis of p38 and HSP27. Protein lysates were 
prepared from GM18366 (ataxia-telangiectasia and rad3-related Seckel [ATR-
S]) and AG16409 (normal dermal fibroblast strains [NDFs]) cells. Expression 
levels were compared for phosphorylated p38 (p-p38), p38, phosphorylated 
HSP27 (p-HSP27), and HSP27. Loadings were normalized for p38. For each 
series A and B, a control lane has been added (with ATR-S used as control for 
NDFs and vice versa). Lanes are D, dimethyl sulfoxide (DMSO); VX, VX-745; 
SB, SB203580; B, BIRB 796. “An” are AG16409 cells treated with 30 μM 
anisomycin for 45 min to activate p38 and phosphorylate HSP27. The bands 
marked with arrows in lanes VX and B of A are nonspecific bands that are also 
seen in B.
Figure 3. Immunoblot analysis of cell cycle proteins and caveolin-1. Protein 
lysates were prepared from low population doubling (PD) GM18366 (ataxia-tel-
angiectasia and rad3-related Seckel [ATR-S]), AG16409 (normal dermal fibro-
blast strains [NDFs]), and AG05229 (Werner syndrome [WS]) cells. Expression 
levels were compared for p16INK4A, p21WAF1, phospho-caveolin-1 (p-cav), caveo-
lin-1 (cav), phospho-cofilin (p-cof), cofilin (cof), and MK2. Actin is used as 
loading control for each panel. Lanes are D, dimethyl sulfoxide (DMSO); VX, 
VX-745; SB, SB203580; and B, BIRB 796. The horizontal arrow indicates the 
24 kDa p-cav band and the diagonal arrow indicates activated MK2. The verti-
cal line in C indicates that the single lanes have been cut and pasted from the 
same gels as the rest of the samples, however, the images have been handled in 
the same manner otherwise.
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cells at senescence (not shown). In contrast, expression of 
the p53 shRNA resulted in evasion of senescence and gener-
ated rapidly growing cultures. Eventually, approximately 15 
PDs beyond M1, the GM18366p53 cells entered a senescence-
like state termed Mint that has been described previously for 
p53-abrogated human fibroblasts (41) with the cells being 
enlarged with extensive F-actin stress fibers (Figure 4D).
In the GM18366p53 cells at Mint p53, protein levels were 
very low compared with cells at M1, showing that the 
shRNA had successfully abrogated p53 (Figure  4F). In 
addition, the level of the p53 target p21WAF1 was very low, 
whereas p16INK4A levels had increased compared with M1 
(Figure 4F). Interestingly, the levels of both caveolin-1 and 
p-caveolin-1 increased in the GM18366p53 cells compared 
with cells at M1.
Extension of the Replicative Capacity of ATR-Seckel 
Syndrome Cells By Ectopic hTert Expression
GM18366 cells were infected with retroviruses express-
ing puromycin resistance and hTert or puromycin resistance 
only. Drug-resistant cultures were selected and designated 
as GM18366hTert and GM18366puro.
GM18366 cells were infected at PD 7 and the GM18366puro 
control managed 19 PDs before reaching M1 (Figure 4B). 
The GM18366hTert culture achieved greater than 65 PDs and 
showed little sign of senescing, indeed these lines are still 
growing today. However, although apparently immortalized, 
GM18366hTert cells retained many of the characteristics 
of young GM18366 cells, in that many were enlarged 
with F-actin stress fibers (Figure  4E), and treatment of 
GM18366hTert cells with any of the p38 inhibitors corrected 
Figure 4. Effects of p53 abrogation and ectopic hTert expression on the growth of ataxia-telangiectasia and rad3 (ATR)-related Seckel cells. Growth in population 
doublings (PDs) vs days for (A) GM18366p53 cells, (B) GM18366hTert cells, and (C) GM18366hTert cells treated with p38 inhibitors as indicated. In B and C, the arrow 
indicates the point at which inhibitor treatment of GM18366hTert began. Observation of F-actin stress fibers in (D) GM18366p53 cells at Mint and (E) GM18366hTert 
cells. Bar = 100 μm. (F) Immunoblot analysis for GM18366 cells (proteins analyzed as for Figures 2 and 3; the arrow on the p-p38 row shows activated p38). 
Cy = low PD cycling cells; M1 = cells at senescence; p53 = GM18366 abrogated for p53; hTert = GM18366 cells infected with hTert.
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this (not shown). As well as correcting the morphology, p38 
inhibitors increased the growth rate of GM18366hTert cells 
(Figure  4C), with VX-745 having the smallest effect and 
BIRB 796 the greatest effect, similar to that seen with primary 
GM18366 cells. This is compatible with the observation that 
p38 was still active in GM18366hTert cells (Figure 4F).
The levels of p16INK4A, p21WAF1, p53, caveolin-1, and 
p-caveolin-1 in GM18366hTert cells were all similar to that 
seen in low PD GM18366 cells (Figure 4F).
Discussion
Our data demonstrate that replicative senescence in ATR-
deficient fibroblasts is qualitatively similar to that seen in 
normal human fibroblasts. Senescent cells feature irrevers-
ible growth arrest involving the upregulation of cell cycle 
inhibitors such as p21WAF1 and p16INK4A and have a charac-
teristic enlarged and flattened morphology (42). Replicative 
senescence in NDFs is due to telomere shortening that 
activates the p53-signalling pathway (43). Replicative 
senescence in ATR-Seckel cells is p53 dependent, although 
p16INK4A and p21WAF1 levels were not elevated at M1 com-
pared with low PD cells. This may be due to these CdkIs 
already being elevated in low PD ATR-Seckel cells with 
p16INK4A being elevated further at Mint (as is seen in NDFs). 
A further similarity is that replicative senescence in ATR-
Seckel cells is telomere dependent; ectopic expression of 
human telomerase–enabled ATR-Seckel cells to bypass 
senescence and proliferate continuously.
However, despite the normal replicative senescence 
mechanism, ATR-Seckel cells had a reduced replicative 
capacity compared with NDFs, an observation that is novel 
to this work. Although the GM18366 replicative capac-
ity was not significantly reduced compared with the three 
NDFs used here, it was significantly reduced (p < .036; z 
test) when the replicative capacity of a further five previ-
ously studied NDFs (8) that were grown under the same 
conditions were added to the data (Supplementary Table 1).
As with WS fibroblasts, many ATR-Seckel fibroblasts 
displayed features suggestive of activation of p38, such as 
an enlarged morphology with extensive F-actin stress fibers, 
and molecular profiling indeed revealed both activated p38 
and phosphorylated HSP27 (a downstream target of p38). 
Furthermore, the replicative capacity of ATR-Seckel cells 
was significantly increased by treatment with p38 inhibitors, 
with the replicative capacity using BIRB 796 now within the 
range seen for normal fibroblasts, and the senescent (aged) 
morphology reverted to that seen in NDFs. The effective-
ness of each inhibitor on replicative capacity and cellular 
morphology correlated with the degree to which the p38 
pathway was inhibited, as assessed by the level of pHSP27. 
Overall this indicates that, like WS fibroblasts, ATR-Seckel 
cells undergo some degree of p38-dependent SIPS.
Molecular profiling provided further insights as to 
the potential mechanism whereby p38 activation leads 
to cell cycle arrest. The CdkIs p16INK4A and p21WAF1 were 
both upregulated in low PD ATR-Seckel cells. Although 
p38-dependent SIPS can be transduced by either CdkI 
(4,44,45), and p38 is known to activate p21WAF1 via direct 
phosphorylation, or by activation of p53 (46), p38 inhibition 
in ATR-Seckel cells reduces p16INK4A levels but not p21WAF1, 
suggesting that p38-dependent SIPS in ATR-Seckel cells 
is transduced, at least in part, via p16INK4A. Thus, the SIPS 
process in ATR-Seckel cells is similar to that seen in cells 
prematurely senesced by expression of oncogenic ras that 
results in upregulation of p16INK4A (44,47) and contrasts with 
WS where p38-dependent SIPS is transduced by p21WAF1(4).
Another pathway that appears to be differently implicated 
in senescence in WS and ATR-Seckel cells involves caveo-
lin-1. This is the principal component of caveolae, which 
are 50–100 nm flask-shaped invaginations of the cell mem-
brane found in many cell types including fibroblasts (48). 
Caveolin-1 acts as a scaffolding protein to compartmental-
ize and functionally regulate signalling molecules within 
caveolar membranes (40). Caveolin-1 upregulation plays a 
key role in SIPS in MEFs and human chondrocytes under 
serum starvation, oxidative stress, or IL-1β treatment (48–
50). SIPS can be prevented using siRNA caveolin-1 knock-
down or MEFs from caveolin-1 null mice (51). Caveolin-1 
is thought to activate the p53/p21WAF1 signalling pathway 
(48), and in turn it is regulated by p38 via both increased 
caveolin-1 protein and elevated phosphorylation (52). In 
ATR-Seckel cells, p-caveolin-1 levels were high, and this 
was reduced by treatment with p38 inhibitors, although 
elevated caveolin-1 protein was not observed. However, 
the observation that p21WAF1 levels were not reduced by 
p38 inhibition suggests that the caveolin-1 phosphoryla-
tion seen in ATR-Seckel cells does not induce senescence 
via p21WAF1. This contrasts with the situation in low PD WS 
cells, where caveolin-1, p-caveolin-1, and p21WAF1 are all 
regulated by p38.
In summary, our data support the hypothesis that the repli-
cation stress due to lack (or low levels) of ATR seen in ATR-
Seckel cells results in SIPS via p38-dependent upregulation 
of p16INK4A and potentially via phosphorylated caveolin-1. 
Furthermore, this SIPS appears to be independent of tel-
omere erosion, as immortalized GM18366hTert cells maintain 
a stressed phenotype showing p38 activation and levels of 
p16INK4A and p21WAF1 similar to that seen in low PD GM18366 
cells. As replicative senescence in ATR-Seckel cells appears 
qualitatively normal, p38 activation and/or SIPS synergizes 
with the normal telomere-dependent senescence to yield the 
reduced replicative capacity seen in ATR-Seckel cells. This 
SIPS results in many young ATR-Seckel cells having an 
aged phenotype and molecular profile that resembles cells at 
M1, thus, ATR-Seckel cells undergo accelerated aging.
Overall, these results suggest a strong overlap in the 
cellular phenotype of WS and ATR-Seckel cells as related 
to senescence-related phenotypes. In both WS and ATR-
Seckel fibroblasts, replicative senescence is telomere 
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driven and p53 dependent, and they show high levels of 
activated p38 and SIPS (this work and [4,35]). A  further 
similarity is that SIPS in both WS and ATR-Seckel cells 
is independent of telomeres but synergizes with telomere-
dependent senescence to reduce the replicative capacity. As 
WRNp and ATR interact in a common signalling pathway, 
we hypothesize that both WS and ATR-Seckel fibroblasts 
undergo SIPS resulting from increased replication stress. 
This SIPS may lead to aspects of the whole-body phenotypes 
of both ATR-Seckel and WS such as growth retardation and 
premature aging due in part to a reduction in cellular division 
capacity and an accelerated rate of build up of senescent cells 
(3,10). The chronic activation of p38 may also contribute to 
accelerated aging and the disease predisposition spectrum 
of these patients—so-called inflamm-aging (53).
Although the similarities between the two syndromes are 
marked at the cellular level, an important question remains 
as to why, if ATR and WRNp share a common signalling 
pathway, there are so many nonoverlapping phenotypic 
symptoms? This may relate to ATR having a wider and more 
pivotal role in cell physiology; ATR is an essential protein, 
whereas WRNp is not. It would be surprising, therefore, for 
ATR and WS to yield identical phenotypes when mutated. 
A  further complication is that ATR-Seckel individuals 
appear to have shorter lives than WS individuals (15,17), 
so perhaps have insufficient time to develop as dramatic a 
progeroid phenotype as seen in WS. Nevertheless, the mul-
tiple observations of replication stress–driven p38 activation 
in a subset of human progerias strengthen the potential rel-
evance of this mechanism to human aging (4,8). Although 
ultimately ATR-Seckel and WS are “private” mechanisms of 
aging (insofar as they are driven by mutations not found in 
normal individuals), we would note that both pathways rap-
idly converge on a core signalling pathway that is subject to 
substantial regulation by cell intrinsic and extrinsic factors. 
This in turn raises the possibility that normal human aging 
might be affected, even if temporarily, by differential activa-
tion of the p38 pathway as a result of other activating cir-
cumstances. Finally, we would note that the accelerate cell 
aging phenotype of both ATR-Seckel and WS fibroblasts 
can be abrogated by small molecule drugs that target p38.
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